Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. The company is headquartered in Wayne, Pennsylvania and currently employs 14 full-time employees. The company went IPO on 2014-12-18. The firm is developing a pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Its QTORIN product candidates are developed to accommodate the cargo at high concentrations in order to drive sufficient drug to its target deep in the epidermis and dermis. The firm's lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin), is being evaluated in the Phase III SELVA clinical trial in microcystic lymphatic malformations and the Phase II TOIVA clinical trial in cutaneous venous malformations.
Follow-Up Questions
Who is the CEO of Palvella Therapeutics Inc?
Mr. Wesley Kaupinen is the President of Palvella Therapeutics Inc, joining the firm since 2024.
What is the price performance of PVLA stock?
The current price of PVLA is $59.04, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Palvella Therapeutics Inc?
Palvella Therapeutics Inc belongs to Biotechnology industry and the sector is Health Care
What is Palvella Therapeutics Inc market cap?
Palvella Therapeutics Inc's current market cap is $652.9M
Is Palvella Therapeutics Inc a buy, sell, or hold?
According to wall street analysts, 15 analysts have made analyst ratings for Palvella Therapeutics Inc, including 3 strong buy, 14 buy, 1 hold, 0 sell, and 3 strong sell
